Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events? View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-10

AUTHORS

Shelley R. Salpeter

ABSTRACT

There has been recent uncertainty about whether the inhaled anticholinergic agents ipratropium bromide and tiotropium bromide increase or decrease cardiovascular risk in the treatment of patients with chronic obstructive pulmonary disease (COPD). This article synthesizes the available data in order to understand the controversy.COPD is a common cause of hospitalizations and is a rapidly increasing cause of mortality worldwide. Despite the heavy burden of COPD-related illness, the leading cause of hospitalization in COPD patients is cardiovascular disease. This link between COPD and cardiovascular disease is in part due to the fact that both diseases share common risk factors, such as tobacco smoking and advanced age. It is also hypothesized that systemic inflammation in COPD increases the risk for cardiac events such as myocardial infarction.Inhaled anticholinergics reduce COPD-related hospitalizations and respiratory deaths compared with placebo, and tiotropium bromide is more effective than ipratropium bromide. In randomized trials, patients receiving tiotropium bromide have lower discontinuation rates than those receiving placebo and, therefore, contribute more person-years to the analyses. In a recent large 4-year tiotropium bromide trial, the proportion of patients who died was similar in the tiotropium bromide and placebo groups, whereas the death rate per person-years was lower with tiotropium bromide, indicating longer overall survival.There has been conflicting evidence concerning cardiovascular risk associated with inhaled anticholinergics. One meta-analysis found that the risk for major cardiovascular events was higher with anticholinergics compared with placebo or active comparator controls, whereas two subsequent meta-analyses that included new trial data found no difference in risk. In a recent pooled safety analysis, when incidence rates of events over time were evaluated, tiotropium bromide was associated with a lower rate of major cardiovascular events and cardiovascular deaths compared with placebo. This risk reduction was mainly because of a reduction in serious cardiac events such as myocardial infarction and congestive heart failure.In conclusion, inhaled anticholinergics, especially tiotropium bromide, reduce COPD-related hospitalizations and deaths, and may improve total survival over time. Many COPD patients have concomitant cardiovascular disease processes. Thus, trials may observe more cardiovascular events associated with anticholinergics than with placebo, but this differential is eliminated when evaluating the rate of events per person-years of exposure. New evidence indicates that tiotropium bromide may actually reduce the incidence of cardiovascular events and deaths over time. It is possible that the reduction in respiratory morbidity could improve functional status and reduce adverse cardiac outcomes over time. Further studies are needed to address this important issue. More... »

PAGES

2025-2033

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/11318580-000000000-00000

DOI

http://dx.doi.org/10.2165/11318580-000000000-00000

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034844298

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19791824


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bronchodilator Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholinergic Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ipratropium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pulmonary Disease, Chronic Obstructive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Scopolamine Derivatives", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tiotropium Bromide", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.415182.b", 
          "name": [
            "Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA", 
            "Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salpeter", 
        "givenName": "Shelley R.", 
        "id": "sg:person.012160071167.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012160071167.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00002512-200421060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044511580", 
          "https://doi.org/10.2165/00002512-200421060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1385/criai:31:2:219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026725163", 
          "https://doi.org/10.1385/criai:31:2:219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1525-1497.2006.00507.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030196607", 
          "https://doi.org/10.1111/j.1525-1497.2006.00507.x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-10", 
    "datePublishedReg": "2009-10-01", 
    "description": "There has been recent uncertainty about whether the inhaled anticholinergic agents ipratropium bromide and tiotropium bromide increase or decrease cardiovascular risk in the treatment of patients with chronic obstructive pulmonary disease (COPD). This article synthesizes the available data in order to understand the controversy.COPD is a common cause of hospitalizations and is a rapidly increasing cause of mortality worldwide. Despite the heavy burden of COPD-related illness, the leading cause of hospitalization in COPD patients is cardiovascular disease. This link between COPD and cardiovascular disease is in part due to the fact that both diseases share common risk factors, such as tobacco smoking and advanced age. It is also hypothesized that systemic inflammation in COPD increases the risk for cardiac events such as myocardial infarction.Inhaled anticholinergics reduce COPD-related hospitalizations and respiratory deaths compared with placebo, and tiotropium bromide is more effective than ipratropium bromide. In randomized trials, patients receiving tiotropium bromide have lower discontinuation rates than those receiving placebo and, therefore, contribute more person-years to the analyses. In a recent large 4-year tiotropium bromide trial, the proportion of patients who died was similar in the tiotropium bromide and placebo groups, whereas the death rate per person-years was lower with tiotropium bromide, indicating longer overall survival.There has been conflicting evidence concerning cardiovascular risk associated with inhaled anticholinergics. One meta-analysis found that the risk for major cardiovascular events was higher with anticholinergics compared with placebo or active comparator controls, whereas two subsequent meta-analyses that included new trial data found no difference in risk. In a recent pooled safety analysis, when incidence rates of events over time were evaluated, tiotropium bromide was associated with a lower rate of major cardiovascular events and cardiovascular deaths compared with placebo. This risk reduction was mainly because of a reduction in serious cardiac events such as myocardial infarction and congestive heart failure.In conclusion, inhaled anticholinergics, especially tiotropium bromide, reduce COPD-related hospitalizations and deaths, and may improve total survival over time. Many COPD patients have concomitant cardiovascular disease processes. Thus, trials may observe more cardiovascular events associated with anticholinergics than with placebo, but this differential is eliminated when evaluating the rate of events per person-years of exposure. New evidence indicates that tiotropium bromide may actually reduce the incidence of cardiovascular events and deaths over time. It is possible that the reduction in respiratory morbidity could improve functional status and reduce adverse cardiac outcomes over time. Further studies are needed to address this important issue.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/11318580-000000000-00000", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "15", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "69"
      }
    ], 
    "keywords": [
      "chronic obstructive pulmonary disease", 
      "major cardiovascular events", 
      "COPD-related hospitalization", 
      "tiotropium bromide", 
      "cardiovascular events", 
      "COPD patients", 
      "cardiovascular risk", 
      "cardiac events", 
      "ipratropium bromide", 
      "myocardial infarction", 
      "cardiovascular disease", 
      "anticholinergic agent ipratropium bromide", 
      "active comparator controls", 
      "pooled safety analysis", 
      "serious cardiac events", 
      "low discontinuation rate", 
      "proportion of patients", 
      "obstructive pulmonary disease", 
      "cause of hospitalization", 
      "congestive heart failure", 
      "more cardiovascular events", 
      "adverse cardiac outcomes", 
      "longer overall survival", 
      "treatment of patients", 
      "new trial data", 
      "common risk factors", 
      "cardiovascular disease processes", 
      "cause of mortality", 
      "placebo group", 
      "cardiovascular death", 
      "systemic inflammation", 
      "discontinuation rates", 
      "overall survival", 
      "respiratory morbidity", 
      "cardiac outcomes", 
      "pulmonary disease", 
      "tobacco smoking", 
      "heart failure", 
      "randomized trials", 
      "functional status", 
      "risk factors", 
      "advanced age", 
      "respiratory deaths", 
      "incidence rate", 
      "common cause", 
      "placebo", 
      "anticholinergics", 
      "disease process", 
      "patients", 
      "hospitalization", 
      "total survival", 
      "trial data", 
      "death rate", 
      "disease", 
      "rate of events", 
      "death", 
      "trials", 
      "infarction", 
      "Further studies", 
      "risk", 
      "risk reduction", 
      "lower rates", 
      "cause", 
      "survival", 
      "heavy burden", 
      "comparator control", 
      "morbidity", 
      "smoking", 
      "inflammation", 
      "illness", 
      "mortality", 
      "available data", 
      "incidence", 
      "events", 
      "rate", 
      "evidence", 
      "age", 
      "outcomes", 
      "treatment", 
      "burden", 
      "new evidence", 
      "reduction", 
      "exposure", 
      "increase", 
      "conclusion", 
      "status", 
      "failure", 
      "group", 
      "safety analysis", 
      "proportion", 
      "time", 
      "factors", 
      "data", 
      "controversy", 
      "differences", 
      "control", 
      "study", 
      "recent uncertainty", 
      "analysis", 
      "differential", 
      "bromide", 
      "bromide increase", 
      "part", 
      "important issue", 
      "link", 
      "article", 
      "fact", 
      "issues", 
      "order", 
      "process", 
      "uncertainty"
    ], 
    "name": "Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events?", 
    "pagination": "2025-2033", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034844298"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/11318580-000000000-00000"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19791824"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/11318580-000000000-00000", 
      "https://app.dimensions.ai/details/publication/pub.1034844298"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_496.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/11318580-000000000-00000"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/11318580-000000000-00000'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/11318580-000000000-00000'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/11318580-000000000-00000'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/11318580-000000000-00000'


 

This table displays all metadata directly associated to this object as RDF triples.

229 TRIPLES      21 PREDICATES      150 URIs      138 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/11318580-000000000-00000 schema:about N0229e28a29e94dbd90d3fe5f61e5ba59
2 N0367a27a802f4b6aa7832947a386b494
3 N29f1f71a4f1348c5bab817d4574a442a
4 N54be82a1d1f644599d41c1bf86e1f09d
5 N7c54150e786044e3b8397466a3c5be5a
6 N98e3a65d42d44c5e81f3dbb9b6af66ff
7 Nb26150ca1afa4731a11daa2e31de2bb8
8 Ncc3c50b5beec46f68725e271e88a1878
9 Nf22b8e385dd2466799c1115357b36773
10 Nf407f86341b64174ba6fd58de589e650
11 anzsrc-for:11
12 anzsrc-for:1102
13 anzsrc-for:1117
14 schema:author N694f26eba51d48d5bd1c4b5c79521ba8
15 schema:citation sg:pub.10.1111/j.1525-1497.2006.00507.x
16 sg:pub.10.1385/criai:31:2:219
17 sg:pub.10.2165/00002512-200421060-00005
18 schema:datePublished 2009-10
19 schema:datePublishedReg 2009-10-01
20 schema:description There has been recent uncertainty about whether the inhaled anticholinergic agents ipratropium bromide and tiotropium bromide increase or decrease cardiovascular risk in the treatment of patients with chronic obstructive pulmonary disease (COPD). This article synthesizes the available data in order to understand the controversy.COPD is a common cause of hospitalizations and is a rapidly increasing cause of mortality worldwide. Despite the heavy burden of COPD-related illness, the leading cause of hospitalization in COPD patients is cardiovascular disease. This link between COPD and cardiovascular disease is in part due to the fact that both diseases share common risk factors, such as tobacco smoking and advanced age. It is also hypothesized that systemic inflammation in COPD increases the risk for cardiac events such as myocardial infarction.Inhaled anticholinergics reduce COPD-related hospitalizations and respiratory deaths compared with placebo, and tiotropium bromide is more effective than ipratropium bromide. In randomized trials, patients receiving tiotropium bromide have lower discontinuation rates than those receiving placebo and, therefore, contribute more person-years to the analyses. In a recent large 4-year tiotropium bromide trial, the proportion of patients who died was similar in the tiotropium bromide and placebo groups, whereas the death rate per person-years was lower with tiotropium bromide, indicating longer overall survival.There has been conflicting evidence concerning cardiovascular risk associated with inhaled anticholinergics. One meta-analysis found that the risk for major cardiovascular events was higher with anticholinergics compared with placebo or active comparator controls, whereas two subsequent meta-analyses that included new trial data found no difference in risk. In a recent pooled safety analysis, when incidence rates of events over time were evaluated, tiotropium bromide was associated with a lower rate of major cardiovascular events and cardiovascular deaths compared with placebo. This risk reduction was mainly because of a reduction in serious cardiac events such as myocardial infarction and congestive heart failure.In conclusion, inhaled anticholinergics, especially tiotropium bromide, reduce COPD-related hospitalizations and deaths, and may improve total survival over time. Many COPD patients have concomitant cardiovascular disease processes. Thus, trials may observe more cardiovascular events associated with anticholinergics than with placebo, but this differential is eliminated when evaluating the rate of events per person-years of exposure. New evidence indicates that tiotropium bromide may actually reduce the incidence of cardiovascular events and deaths over time. It is possible that the reduction in respiratory morbidity could improve functional status and reduce adverse cardiac outcomes over time. Further studies are needed to address this important issue.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N6aac9a48bec94fb6819e6ebfe5853a6d
24 N94b7d45312ea4adcb4ff453fb673e974
25 sg:journal.1084788
26 schema:keywords COPD patients
27 COPD-related hospitalization
28 Further studies
29 active comparator controls
30 advanced age
31 adverse cardiac outcomes
32 age
33 analysis
34 anticholinergic agent ipratropium bromide
35 anticholinergics
36 article
37 available data
38 bromide
39 bromide increase
40 burden
41 cardiac events
42 cardiac outcomes
43 cardiovascular death
44 cardiovascular disease
45 cardiovascular disease processes
46 cardiovascular events
47 cardiovascular risk
48 cause
49 cause of hospitalization
50 cause of mortality
51 chronic obstructive pulmonary disease
52 common cause
53 common risk factors
54 comparator control
55 conclusion
56 congestive heart failure
57 control
58 controversy
59 data
60 death
61 death rate
62 differences
63 differential
64 discontinuation rates
65 disease
66 disease process
67 events
68 evidence
69 exposure
70 fact
71 factors
72 failure
73 functional status
74 group
75 heart failure
76 heavy burden
77 hospitalization
78 illness
79 important issue
80 incidence
81 incidence rate
82 increase
83 infarction
84 inflammation
85 ipratropium bromide
86 issues
87 link
88 longer overall survival
89 low discontinuation rate
90 lower rates
91 major cardiovascular events
92 morbidity
93 more cardiovascular events
94 mortality
95 myocardial infarction
96 new evidence
97 new trial data
98 obstructive pulmonary disease
99 order
100 outcomes
101 overall survival
102 part
103 patients
104 placebo
105 placebo group
106 pooled safety analysis
107 process
108 proportion
109 proportion of patients
110 pulmonary disease
111 randomized trials
112 rate
113 rate of events
114 recent uncertainty
115 reduction
116 respiratory deaths
117 respiratory morbidity
118 risk
119 risk factors
120 risk reduction
121 safety analysis
122 serious cardiac events
123 smoking
124 status
125 study
126 survival
127 systemic inflammation
128 time
129 tiotropium bromide
130 tobacco smoking
131 total survival
132 treatment
133 treatment of patients
134 trial data
135 trials
136 uncertainty
137 schema:name Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events?
138 schema:pagination 2025-2033
139 schema:productId N17af23b417e54998b7433d4e21da5386
140 N2fe43547af3442cc818ad088f463819b
141 N5de784fa13dc4c7ea84ec774cb6f6d5c
142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034844298
143 https://doi.org/10.2165/11318580-000000000-00000
144 schema:sdDatePublished 2022-12-01T06:28
145 schema:sdLicense https://scigraph.springernature.com/explorer/license/
146 schema:sdPublisher N698fd7a6a4f24d79aa80276d2d07762f
147 schema:url https://doi.org/10.2165/11318580-000000000-00000
148 sgo:license sg:explorer/license/
149 sgo:sdDataset articles
150 rdf:type schema:ScholarlyArticle
151 N0229e28a29e94dbd90d3fe5f61e5ba59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Bronchodilator Agents
153 rdf:type schema:DefinedTerm
154 N0367a27a802f4b6aa7832947a386b494 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Ipratropium
156 rdf:type schema:DefinedTerm
157 N17af23b417e54998b7433d4e21da5386 schema:name dimensions_id
158 schema:value pub.1034844298
159 rdf:type schema:PropertyValue
160 N29f1f71a4f1348c5bab817d4574a442a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Scopolamine Derivatives
162 rdf:type schema:DefinedTerm
163 N2fe43547af3442cc818ad088f463819b schema:name doi
164 schema:value 10.2165/11318580-000000000-00000
165 rdf:type schema:PropertyValue
166 N54be82a1d1f644599d41c1bf86e1f09d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Humans
168 rdf:type schema:DefinedTerm
169 N5de784fa13dc4c7ea84ec774cb6f6d5c schema:name pubmed_id
170 schema:value 19791824
171 rdf:type schema:PropertyValue
172 N694f26eba51d48d5bd1c4b5c79521ba8 rdf:first sg:person.012160071167.38
173 rdf:rest rdf:nil
174 N698fd7a6a4f24d79aa80276d2d07762f schema:name Springer Nature - SN SciGraph project
175 rdf:type schema:Organization
176 N6aac9a48bec94fb6819e6ebfe5853a6d schema:issueNumber 15
177 rdf:type schema:PublicationIssue
178 N7c54150e786044e3b8397466a3c5be5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Administration, Inhalation
180 rdf:type schema:DefinedTerm
181 N94b7d45312ea4adcb4ff453fb673e974 schema:volumeNumber 69
182 rdf:type schema:PublicationVolume
183 N98e3a65d42d44c5e81f3dbb9b6af66ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Cholinergic Antagonists
185 rdf:type schema:DefinedTerm
186 Nb26150ca1afa4731a11daa2e31de2bb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Tiotropium Bromide
188 rdf:type schema:DefinedTerm
189 Ncc3c50b5beec46f68725e271e88a1878 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Pulmonary Disease, Chronic Obstructive
191 rdf:type schema:DefinedTerm
192 Nf22b8e385dd2466799c1115357b36773 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Risk
194 rdf:type schema:DefinedTerm
195 Nf407f86341b64174ba6fd58de589e650 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Cardiovascular Diseases
197 rdf:type schema:DefinedTerm
198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical and Health Sciences
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
202 schema:name Cardiorespiratory Medicine and Haematology
203 rdf:type schema:DefinedTerm
204 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
205 schema:name Public Health and Health Services
206 rdf:type schema:DefinedTerm
207 sg:journal.1084788 schema:issn 0012-6667
208 1179-1950
209 schema:name Drugs
210 schema:publisher Springer Nature
211 rdf:type schema:Periodical
212 sg:person.012160071167.38 schema:affiliation grid-institutes:grid.415182.b
213 schema:familyName Salpeter
214 schema:givenName Shelley R.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012160071167.38
216 rdf:type schema:Person
217 sg:pub.10.1111/j.1525-1497.2006.00507.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1030196607
218 https://doi.org/10.1111/j.1525-1497.2006.00507.x
219 rdf:type schema:CreativeWork
220 sg:pub.10.1385/criai:31:2:219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026725163
221 https://doi.org/10.1385/criai:31:2:219
222 rdf:type schema:CreativeWork
223 sg:pub.10.2165/00002512-200421060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044511580
224 https://doi.org/10.2165/00002512-200421060-00005
225 rdf:type schema:CreativeWork
226 grid-institutes:grid.415182.b schema:alternateName Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, USA
227 schema:name Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, USA
228 Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA
229 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...